Tue, 04 Oct 2022

NEW YORK, NY / ACCESSWIRE / August 8, 2022 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Bronstein, Gewirtz and Grossman, LLC, Monday, August 8, 2022, Press release picture

TG Therapeutics, Inc. (NASDAQ:TGTX)

Class Period: January 15, 2020 - May 31, 2022

Deadline: September 16, 2022
For more info:www.bgandg.com/tgtx.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab and Umbralisib; (2) accordingly, it was unlikely that the Company would be able to obtain FDA approval of the Umbralisib MZL/FL NDA, the U2 BLA, the U2 sNDA, or the Ublituximab RMS BLA in their current forms; (3) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (4) therefore, the Company's public statements were materially false and misleading at all relevant times.

17 Education & Technology Group Inc. (NASDAQ:YQ)

Class Period: pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Registration Statement') issued in connection with 17EdTech December 2020 initial public offering (the 'IPO' or 'Offering').

Deadline: September 19, 2022
For more info:www.bgandg.com/yq.

The Complaint alleges that the Registration Statement featured false and/or misleading statements and/or failed to disclose that: (1) 17EdTech's K-12 Academic AST Services would end less than a year after the IPO; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Enochian Biosciences Inc. (NASDAQ:ENOB)

Class Period: September 24, 2020 - May 31, 2022

Deadline: September 26, 2022
For more info:www.bgandg.com/enob.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Gumrukcu was not a licensed doctor and had no verifiable degrees beyond high school; (2) accordingly, the scientific and technological underpinnings of Enochian's product pipeline, purportedly invented by Gumrukcu, were dubious at best; (3) accordingly, the Defendants had significantly overstated the commercial prospects for the Company's product pipeline; (4) Enochian's senior leadership knew Gumrukcu had a criminal history that included fraud; (5) accordingly, Enochian's reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected the Company to a heightened risk of reputational and financial harm, as well as threatened the integrity of the Company's scientific findings; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/710419/TGTX-YQ-ENOB-Class-Actions-Deadlines-Bronstein-Gewirtz-Grossman-LLC-A-Leading-Class-Action-Firm-Reminds-Investors-to-Contact-the-Firm-and-Actively-Participate

More Orlando News

Access More

Sign up for The Orlando News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!